Form 4 Filing for Can-Fite BioPharma Ltd.

This filing details a Form 4 submission for Can-Fite BioPharma Ltd. by Pnina Fishman, Chief Scientific Officer and Director. The transaction, dated June 4, 2026, involves the acquisition of 24,000 options to purchase ordinary shares with an exercise price of $2.043 per share. These options are part of the company's 2026 Share Option Plan and vest in sixteen equal quarterly installments starting September 4, 2026, and concluding on April 6, 2030, contingent upon continued service. The options were granted under specific Israeli tax regulations requiring a trustee to hold the securities. Following this transaction, the reporting owner holds 34,299 ordinary shares. The filing also notes the conversion of the exercise price from New Israeli Shekels to USD based on the exchange rate on June 5, 2026.